Achieving sufficient delivery across the blood–brain barrier is a key challenge in the
development of drugs to treat central nervous system (CNS) disorders. This is particularly …

Today, bio-medical efforts are entering the subcellular level, which is witnessed with the fast-
developing fields of nanomedicine, nanodiagnostics and nanotherapy in conjunction with …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

The development of targeted medicine has greatly expanded treatment options and spurred
new research avenues in cancer therapeutics, with monoclonal antibodies (mAbs) emerging …

A nanobody (Nb) is a registered trademark of Ablynx, referring to the single antigen‐binding
domain of heavy chain‐only antibodies (HCAbs) that are circulating in Camelidae. Nbs are …

Therapies directed toward the central nervous system remain difficult to translate into
improved clinical outcomes. This is largely due to the blood–brain barrier (BBB), arguably …

Highlights•Nanobodies (Nbs) are camelid-derived single-domain antibodies.•Nbs have
powerful binding and inhibitory capacity with great therapeutic potential.•Nbs are used in …

Alzheimer's disease (AD) is one of the biggest human health threats due to increases in
aging of the global population. Unfortunately, drugs for treating AD have been largely …

Increasing evidence suggests that synaptic dysfunction is a key pathophysiological hallmark
in neurodegenerative disorders, including Alzheimer's disease. Understanding the role of …

Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies
have become the largest class of biopharmaceuticals with over 80 antibodies currently …